Patent US4002740A successfully refreshed from Google Patents.
US4002740A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tridecapeptide compositions and methods
Assignee: Individual
•
Filing: 1975-08-21
•
Granted: 1977-01-11
•
Expires: 1995-08-21
Abstract
Abstract There is disclosed a tridecapeptide of the following sequence:
Inventors
- 👤 Gideon Goldstein
- 👤 David H. Schlesinger
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-02 17:24
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/66; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/18; Y10S930/28
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
8 words
A polypeptide of the following sequence: H.sub.2 N--Gly--Glu--Gln--Arg--Lys--Asp--Val--Tyr--Val--Gln--Leu--Tyr--Leu--COOH.
Claim 2
Dependent Claim
8 words
A polypeptide of the following sequence: H.sub.2 N--Gly--Glu--Gln--Arg--Lys--Asp--Val--Tyr--Val--Gln--Leu--Tyr--Leu--COOH.
Claim 3
Dependent Claim
19 words
An intermediate polypeptide of the following sequence: ##STR5## wherein Bzl is benzyl, Tos is tosyl and Z is benzyloxycarbonyl.
Claim 4
Dependent Claim
19 words
An intermediate polypeptide of the following sequence: ##STR5## wherein Bzl is benzyl, Tos is tosyl and Z is benzyloxycarbonyl.
Claim 5
Dependent Claim
43 words
An intermediate polypeptide of the following sequence: ##STR6## wherein Bzl is benzyl, TOS is tosyl, Z is benzyloxycarbonyl, t-BOC is t-butyloxycarbonyl, and the resin is an insoluble polymer having a stable physical form and attached to the adjacent amino acid by covalent bonds.
Claim 6
Dependent Claim
43 words
An intermediate polypeptide of the following sequence: ##STR6## wherein Bzl is benzyl, TOS is tosyl, Z is benzyloxycarbonyl, t-BOC is t-butyloxycarbonyl, and the resin is an insoluble polymer having a stable physical form and attached to the adjacent amino acid by covalent bonds.
Claim 7
Dependent Claim
21 words
A therapeutic composition of matter comprising a therapeutically effective amount of the composition of claim 1 in a pharmaceutically acceptable carrier.
Claim 8
Dependent Claim
26 words
A therapeutic composition of matter according to claim 4 wherein the therapeutically effective amount of the polypeptide is at least about 1 mg/kg of body weight.
Claim 9
Dependent Claim
51 words
A method for the treatment of conditions selected from the group consisting of DiGeorge Syndrome, fungal infections, mycoplasma infections, tuberculosis, leprosy, acute and chronic viral infections and systemic lumpus erythemotosus, said conditions resulting from relative or absolute T-cell deficiencies, which comprises the administration of a composition of claim 4 by injection.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1980-01-11 | 1980-07-12 | 1981-01-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1984-01-11 | 1984-07-12 | 1985-01-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1988-01-11 | 1988-07-12 | 1989-01-11 | $7700.00 | Window Closed / Lapsed |